Apyx Medical Corp (APYX) Latest Filing Signal

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, Apyx Medical Corp's filing signal turned positive.

Apyx Medical Corporation is a surgical aesthetics company focused on elevating lives through its Helium Plasma Platform Technology, marketed as Renuvion for cosmetic surgery and J-Plasma for hospital procedures. The company also offers the AYON Body Contouring System, an integrated platform for fat removal and tissue contraction, which commenced commercial launch in September 2025. Apyx leverages its energy waveform expertise through OEM agreements with other medical device manufacturers, contributing 14.2% of its 2025 revenue, while its core Surgical Aesthetics segment generated 85.8% of revenue. The company operates manufacturing facilities in Clearwater, Florida, and Sofia, Bulgaria, and has expanded its reach into China with Renuvion. Apyx is navigating a competitive landscape and regulatory environment, with a strategic focus on advancing Renuvion's adoption in the cosmetic surgery market.

Revenue is primarily driven by sales of its Renuvion and J-Plasma products within the Surgical Aesthetics segment, which includes capital equipment like generators and single-use handpieces. The OEM segment contributes revenue through contract manufacturing and product sales to other medical device manufacturers.